Mercury Biopharmaceutical Corporation (TPEX:6932)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.90
+0.30 (2.38%)
Apr 24, 2025, 1:28 PM CST
-17.04%
Market Cap 5.32B
Revenue (ttm) 4.96M
Net Income (ttm) -50.57M
Shares Out 421.85M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 128,224
Average Volume 278,629
Open 12.40
Previous Close 12.60
Day's Range 12.40 - 12.90
52-Week Range 10.10 - 17.60
Beta -2.66
RSI 34.37
Earnings Date Apr 24, 2025

About Mercury Biopharmaceutical

Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pec... [Read more]

Sector Healthcare
Founded 2019
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6932
Full Company Profile

Financial Performance

In 2024, Mercury Biopharmaceutical's revenue was 4.96 million, an increase of 380.45% compared to the previous year's 1.03 million. Losses were -50.57 million, 15.4% more than in 2023.

Financial Statements

News

There is no news available yet.